Comparison of Cellect Biotechnology Ltd. (APOP) and Aratana Therapeutics Inc. (NASDAQ:PETX)

Both Cellect Biotechnology Ltd. (NASDAQ:APOP) and Aratana Therapeutics Inc. (NASDAQ:PETX) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellect Biotechnology Ltd. N/A 0.00 N/A -0.85 0.00
Aratana Therapeutics Inc. 40.96M 5.04 21.69M -0.51 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 represents Cellect Biotechnology Ltd. (NASDAQ:APOP) and Aratana Therapeutics Inc. (NASDAQ:PETX)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Cellect Biotechnology Ltd. 0.00% 0% 0%
Aratana Therapeutics Inc. -52.95% -23% -16.1%

Analyst Ratings

The following table given below contains the ratings and recommendations for Cellect Biotechnology Ltd. and Aratana Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellect Biotechnology Ltd. 0 0 0 0.00
Aratana Therapeutics Inc. 0 2 0 2.00

Competitively Aratana Therapeutics Inc. has an average price target of $5, with potential upside of 17.65%.

Insider & Institutional Ownership

Roughly 0% of Cellect Biotechnology Ltd. shares are owned by institutional investors while 68.4% of Aratana Therapeutics Inc. are owned by institutional investors. Insiders owned 54.73% of Cellect Biotechnology Ltd. shares. Competitively, Aratana Therapeutics Inc. has 2% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellect Biotechnology Ltd. -4.19% -33.88% -35.74% -56.13% -57.5% -54.29%
Aratana Therapeutics Inc. -2.77% -9.33% 22.48% 25.15% 16.39% 20.15%

For the past year Cellect Biotechnology Ltd. had bearish trend while Aratana Therapeutics Inc. had bullish trend.


Aratana Therapeutics Inc. beats Cellect Biotechnology Ltd. on 6 of the 10 factors.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.